Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

  • STATUS
    Not Recruiting
  • participants needed
    99
  • sponsor
    Daiichi Sankyo, Inc.
Updated on 24 June 2021
cancer
measurable disease
breast cancer
HER2
trastuzumab
nivolumab
antineoplastic
stage iv breast cancer
erbb2
immune checkpoint inhibitor
mammogram

Summary

This is a study of trastuzumab deruxtecan, which was approved by the FDA (in December 2019) for the treatment of HER2-positive unresectable or metastatic breast cancer following two or more prior anti-HER2 based regimens.

Participants will receive this study drug along with a cancer drug, an immune checkpoint inhibitor, anti-PD1, called nivolumab.

The study will be done in two parts:

  • Part 1 is to identify the recommended dose to use for treatment.
  • Part 2 is to find out how well the combination works, and how safe and tolerable it is.

Description

The purpose of this phase 1b (Part 1, Part 2) study is to assess the combination of a test drug (trastuzumab deruxtecan) with nivolumab in participants with HER2-expressing breast and urothelial cancer who had disease progression during or after prior therapies, did not respond to standard therapies, or for whom no standard therapy is available.

The study will be performed in 2 parts.

  • Part 1 is to test different doses of trastuzumab deruxtecan when given along with a fixed dose of nivolumab, and establish the most effective and the maximum/recommended tolerated dose, when used in combination with nivolumab
  • Part 2 is to assess the efficacy and safety of this dose combination.

Details
Condition Breast Cancer, Transitional cell carcinoma, Urothelial Carcinoma
Treatment Nivolumab, Trastuzumab deruxtecan (DS-8201a), Trastuzumab deruxtecan
Clinical Study IdentifierNCT03523572
SponsorDaiichi Sankyo, Inc.
Last Modified on24 June 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note